Davita Inc vs Sony Group Corp — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while Sony Group Corp trades at $24.07 (market cap $136.87B). The key difference: Sony Group Corp is far larger — about 12.1× Davita Inc's market cap, and Sony Group Corp pays a 0.66% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Sony Group Corp for 96 Days on average.
| DVA | SONY | |
|---|---|---|
Market Cap | $11.29B | $136.87B |
Volume | 582,204 | 5,364,503 |
Sector | Health | Technology |
52-Week High | $240.96 | $30.26 |
52-Week Low | $103.87 | $19.32 |
Typical Hold Time | 113 Days | 96 Days |
Enterprise Value | $24.01B | $134.77B |
Dividend Yield | — | 0.66% |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
Sony trades at $23.52, down 1.38% on the day, with mixed technical signals showing a neutral overall trend. The company reported strong Q4 2025 and Q2 2026 earnings beats but missed Q1 2026 expectations. Revenue remains stable around $12.96T with solid gross margins of 31.82%, though net income margin turned negative at -1.75% for 2026. Analyst sentiment remains bullish with 11 buy ratings versus 5 holds.
Sony presents a compelling value case with reasonable valuation multiples (P/E 19.93, P/S 1.75) and strong cash flow generation. However, recent negative profitability metrics and the Q1 2026 earnings miss highlight execution risks. The company's diversified entertainment portfolio and AI positioning offer growth potential, but investors should monitor margin recovery and content performance.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →